These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26490326)

  • 1. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.
    Keiser MS; Kordower JH; Gonzalez-Alegre P; Davidson BL
    Brain; 2015 Dec; 138(Pt 12):3555-66. PubMed ID: 26490326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.
    Keiser MS; Boudreau RL; Davidson BL
    Mol Ther; 2014 Mar; 22(3):588-595. PubMed ID: 24419082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1.
    Keiser MS; Monteys AM; Corbau R; Gonzalez-Alegre P; Davidson BL
    Ann Neurol; 2016 Nov; 80(5):754-765. PubMed ID: 27686464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinocerebellar Ataxia Type 1: Molecular Mechanisms of Neurodegeneration and Preclinical Studies.
    Pérez Ortiz JM; Orr HT
    Adv Exp Med Biol; 2018; 1049():135-145. PubMed ID: 29427101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism.
    Rousseaux MWC; Tschumperlin T; Lu HC; Lackey EP; Bondar VV; Wan YW; Tan Q; Adamski CJ; Friedrich J; Twaroski K; Chen W; Tolar J; Henzler C; Sharma A; Bajić A; Lin T; Duvick L; Liu Z; Sillitoe RV; Zoghbi HY; Orr HT
    Neuron; 2018 Mar; 97(6):1235-1243.e5. PubMed ID: 29526553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purkinje cell ataxin-1 modulates climbing fiber synaptic input in developing and adult mouse cerebellum.
    Ebner BA; Ingram MA; Barnes JA; Duvick LA; Frisch JL; Clark HB; Zoghbi HY; Ebner TJ; Orr HT
    J Neurosci; 2013 Mar; 33(13):5806-20. PubMed ID: 23536093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model.
    Niewiadomska-Cimicka A; Fievet L; Surdyka M; Jesion E; Keime C; Singer E; Eisenmann A; Kalinowska-Poska Z; Nguyen HHP; Fiszer A; Figiel M; Trottier Y
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of brain region-specific kinases potentiates neurological rescue in Spinocerebellar ataxia type 1.
    Lee WS; Lavery L; Rousseaux MWC; Rutledge EB; Jang Y; Wan YW; Wu SR; Kim W; Al-Ramahi I; Rath S; Adamski CJ; Bondar VV; Tewari A; Soleimani S; Mota S; Yalamanchili HK; Orr HT; Liu Z; Botas J; Zoghbi HY
    EMBO J; 2021 Apr; 40(7):e106106. PubMed ID: 33709453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain.
    Keiser MS; Ranum PT; Yrigollen CM; Carrell EM; Smith GR; Muehlmatt AL; Chen YH; Stein JM; Wolf RL; Radaelli E; Lucas TJ; Gonzalez-Alegre P; Davidson BL
    Nat Med; 2021 Nov; 27(11):1982-1989. PubMed ID: 34663988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.
    Keiser MS; Geoghegan JC; Boudreau RL; Lennox KA; Davidson BL
    Neurobiol Dis; 2013 Aug; 56():6-13. PubMed ID: 23583610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1.
    Edamakanti CR; Do J; Didonna A; Martina M; Opal P
    J Clin Invest; 2018 Jun; 128(6):2252-2265. PubMed ID: 29533923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3β-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1).
    Sánchez I; Balagué E; Matilla-Dueñas A
    Hum Mol Genet; 2016 Sep; 25(18):4021-4040. PubMed ID: 27466200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of ATXN1 S776 phosphorylation reveals the importance of allele-specific targeting in SCA1.
    Nitschke L; Coffin SL; Xhako E; El-Najjar DB; Orengo JP; Alcala E; Dai Y; Wan YW; Liu Z; Orr HT; Zoghbi HY
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33554954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Disease Signatures in the Spinocerebellar Ataxia Type 1 Mouse Cortex.
    Luttik K; Olmos V; Owens A; Khan A; Yun J; Driessen T; Lim J
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.
    Ramachandran PS; Boudreau RL; Schaefer KA; La Spada AR; Davidson BL
    Mol Ther; 2014 Sep; 22(9):1635-42. PubMed ID: 24930601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Strategies for Spinocerebellar Ataxia Type 1.
    Kerkhof LMC; van de Warrenburg BPC; van Roon-Mom WMC; Buijsen RAM
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing mutant ATXN1 nuclear localization improves a spectrum of SCA1-like phenotypes and brain region transcriptomic profiles.
    Handler HP; Duvick L; Mitchell JS; Cvetanovic M; Reighard M; Soles A; Mather KB; Rainwater O; Serres S; Nichols-Meade T; Coffin SL; You Y; Ruis BL; O'Callaghan B; Henzler C; Zoghbi HY; Orr HT
    Neuron; 2023 Feb; 111(4):493-507.e6. PubMed ID: 36577403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect Negative Effect of Mutant Ataxin-1 on Short- and Long-Term Synaptic Plasticity in Mouse Models of Spinocerebellar Ataxia Type 1.
    Shuvaev AN; Belozor OS; Mozhei OI; Shuvaev AN; Fritsler YV; Khilazheva ED; Mosyagina AI; Hirai H; Teschemacher AG; Kasparov S
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spinocerebellar ataxia type 4 (SCA4): Initial pathoanatomical study reveals widespread cerebellar and brainstem degeneration.
    Hellenbroich Y; Gierga K; Reusche E; Schwinger E; Deller T; de Vos RA; Zühlke C; Rüb U
    J Neural Transm (Vienna); 2006 Jul; 113(7):829-43. PubMed ID: 16362839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model.
    Pérez Ortiz JM; Mollema N; Toker N; Adamski CJ; O'Callaghan B; Duvick L; Friedrich J; Walters MA; Strasser J; Hawkinson JE; Zoghbi HY; Henzler C; Orr HT; Lagalwar S
    Neurobiol Dis; 2018 Aug; 116():93-105. PubMed ID: 29758256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.